Novo Nordisk A/S Common Stock (NVO)

87.37
-0.28 (-0.32%)

Novo Nordisk A/S is a global healthcare company focused on developing and manufacturing innovative pharmaceuticals, primarily in the fields of diabetes care and hormone replacement therapy

With a strong emphasis on research and development, the company aims to improve the lives of patients with chronic conditions by providing high-quality medications and medical devices. Novo Nordisk is recognized for its comprehensive approach to diabetes management, including insulin products and modern delivery systems, while also expanding its portfolio to address other serious conditions, such as obesity and rare blood disorders. The company operates in numerous countries, combining expertise in biotechnology with a commitment to sustainability and corporate responsibility.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close87.65
Open87.73
Bid87.22
Ask87.36
Day's Range87.02 - 88.77
52 Week Range81.50 - 148.15
Volume6,066,054
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield1.026 (1.17%)
1 Month Average Volume8,095,745

News & Press Releases

3 Stocks That Could Be Monster Winners in 2025fool.com
Via The Motley Fool · December 29, 2024
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leadersfool.com
Via The Motley Fool · December 29, 2024
10 Top Growth Stocks for 2025fool.com
All 10 have had a good 2024, but I believe the best is yet to come.
Via The Motley Fool · December 28, 2024
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decadesfool.com
Via The Motley Fool · December 28, 2024
Prediction: This Will Be Amazon's Next Big Acquisitionfool.com
Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm over the last several years.
Via The Motley Fool · December 27, 2024
Behind the Scenes of Novo Nordisk's Latest Options Trendsbenzinga.com
Via Benzinga · December 27, 2024
What Analysts Are Saying About Novo Nordisk Stockbenzinga.com
Via Benzinga · December 23, 2024
Elon Musk Admits To Using Weight Loss Medication Criticized By RFK Jr, Says He Prefers Mounjaro Over Miracle Drug Ozempicbenzinga.com
The world's richest man Elon Musk earlier this week admitted to using the weight loss drug Mounjaro.
Via Benzinga · December 28, 2024
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.fool.com
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors.
Via The Motley Fool · December 26, 2024
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?fool.com
Via The Motley Fool · December 26, 2024
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?benzinga.com
Elon Musk sparked conversation about weight-loss drugs and side effects with a Christmas social media post.
Via Benzinga · December 26, 2024
Better Buy: Eli Lilly or Novo Nordisk?fool.com
Novo Nordisk stock crashed 17% on Friday after revealing disappointing trial results.
Via The Motley Fool · December 23, 2024
Tech Stocks Eye Christmas Gains, Microstrategy Tumbles As Bitcoin Dips To $93,000: What's Driving Markets Monday?benzinga.com
Tech stocks began Christmas week with positive momentum, as the Nasdaq 100 rose 0.4% on Monday, building on a 0.7% gain from Friday. The index has now recovered nearly half of the losses sustained following the Federal Reserve's recent policy meeting. Semiconductors stood out as the top-performing sector:
Via Benzinga · December 23, 2024
Novo Nordisk Rises 5% In Premarket As Analyst Dismisses Friday's 17% Plunge As Market Overreactionbenzinga.com
Analysts at Intron Health, led by Naresh Chouhan, suggested that Friday's market reaction was excessively severe.
Via Benzinga · December 23, 2024
Is Merck the Next Big Weight-Loss Stock?fool.com
Via The Motley Fool · December 22, 2024
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?benzinga.com
11 worst-performing large-cap stocks: NVO, VRTX, XPO, SMCI, NU, ARM, MU, PAYC, CTAS, WBD, MNDY. Blame fiscal spending package, Fed rate hike, weak earnings.
Via Benzinga · December 22, 2024
3 Fantastic Stocks That Could Enjoy a Santa Claus Rallyfool.com
Via The Motley Fool · December 21, 2024
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?fool.com
Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off.
Via The Motley Fool · December 21, 2024
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drugbenzinga.com
The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.
Via Benzinga · December 21, 2024
Why Viking Therapeutics Tumbled by More Than 10% This Weekfool.com
Via The Motley Fool · December 20, 2024
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Upfool.com
Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.
Via The Motley Fool · December 20, 2024
MarketBeat Week in Review – 12/16 - 12/20
Stocks were lower this week after the Federal Reserve confirmed fewer rate cuts in 2025, but Friday's rally suggests hope for a Santa Claus rally remains strong
Via MarketBeat · December 21, 2024
Dow Up 752 Points, Extending Rebound From Dramatic Lossestalkmarkets.com
The Dow Jones Industrial Average is in rally mode, reversing its premarket losses to jump 752 points after yesterday snapping its 10-day losing streak.
Via Talk Markets · December 20, 2024
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Reviewinvestors.com
Micron, Vertex, Novo Nordisk and Nike were notable losers on news.
Via Investor's Business Daily · December 20, 2024
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.investors.com
Eli Lilly and Viking Therapeutics jumped on Novo's setback.
Via Investor's Business Daily · December 20, 2024